Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?
No OS Benefit Over Chemotherapy
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
You may also be interested in...
Amidst excitement over the potential of PD-1/PARP inhibitor combos in multiple tumor types, Clovis signs a non-exclusive agreement to test Rubraca with Bristol's Opdivo in ovarian, breast and prostate cancer.
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.